Scientific Reports · 2021 · 18 citations · 42 references
MedicineOncologyPharmacologyCancer PharmacologyMolecular OncologyMolecular PharmacologyOncogenic Signaling PathwaysReceptor Tyrosine Kinase OncogenesTargeted Cancer TherapyTherapeutic ResistanceTyrosine Kinase InhibitorsKinase Inhibitor ResistanceProtein Kinase InhibitorsResistance To Targeted TherapyResistance To Tyrosine Kinase InhibitorsRet InhibitorsTargeted Kinase InhibitionTargeted Resistance MechanismsTrka Signaling
Abstract We have recently described Pz-1, a benzimidazole-based type-2 RET and VEGFR2 inhibitor. Based on a kinome scan, here we show that Pz-1 is also a potent (IC 50 < 1 nM) TRKA/B/C inhibitor. Pz-1 potently inhibited proliferation of human cancer cells carrying either RET- or TRKA oncoproteins (IC 50 ~ 1 nM), with a negligible effect against RET- and TRKA-negative cells. By testing mutations, known to mediate resistance to other compounds, RET G810R/S, but not L730I/V, E732K, V738A and Y806N, showed some degree of resistance to Pz-1. In the case of TRKA, G595R and F589L, but not G667C, showed some degree of resistance. In xenograft models, orally administered Pz-1 almost completely inhibited RET- and TRKA-mutant tumours at 1–3 mg/kg/day but showed a reduced effect on RET/TRKA-negative cancer models. The activity, albeit reduced, on RET/TRKA-negative tumours may be justified by VEGFR2 inhibition. Tumours induced by NIH3T3 cells transfected by RET G810R and TRKA G595R featured resistance to Pz-1, demonstrating that RET or TRKA inhibition is critical for its anti-tumourigenic effect. In conclusion, Pz-1 represents a new powerful kinase inhibitor with distinct activity towards cancers induced by oncogenic RET and TRKA variants, including some mutants displaying resistance to other drugs.
42
Cabozantinib in Progressive Medullary Thyroid Cancer
Rossella Elisei, Martin Schlumberger, Stefan Müller et al. · Journal of Clinical Oncology · 2013 · 1.2K citations · Full text
Medicine, Oncology, Pharmacology +14
Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies
Doron Lipson, Marzia Capelletti, Roman Yelensky et al. · Nature Medicine · 2012 · 869 citations